ABVC BioPharma, Inc. (ABVC)
0.8499
+0.02
(+2.97%)
USD |
NASDAQ |
Sep 02, 16:00
0.8499
0.00 (0.00%)
After-Hours: 20:00
ABVC BioPharma Research and Development Expense (TTM) : 0.1148M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1148M |
| March 31, 2026 | 0.1253M |
| December 31, 2025 | 0.1211M |
| September 30, 2025 | 0.124M |
| June 30, 2025 | 0.1319M |
| March 31, 2025 | 0.1391M |
| December 31, 2024 | 0.1793M |
| September 30, 2024 | 0.2195M |
| June 30, 2024 | 0.323M |
| March 31, 2024 | 0.797M |
| December 31, 2023 | 1.063M |
| September 30, 2023 | 2.486M |
| June 30, 2023 | 2.651M |
| March 31, 2023 | 2.669M |
| December 31, 2022 | 2.694M |
| September 30, 2022 | 1.461M |
| June 30, 2022 | 1.514M |
| March 31, 2022 | 1.103M |
| September 30, 2021 | 0.9269M |
| June 30, 2021 | 0.798M |
| March 31, 2021 | 0.5782M |
| December 31, 2020 | 0.5497M |
| September 30, 2020 | 0.636M |
| June 30, 2020 | 0.7707M |
| March 31, 2020 | 0.7194M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.049M |
| September 30, 2019 | 1.408M |
| June 30, 2019 | 1.194M |
| March 31, 2019 | 1.163M |
| December 31, 2018 | 0.9887M |
| September 30, 2018 | 0.405M |
| June 30, 2018 | 3.476M |
| March 31, 2018 | 3.437M |
| December 31, 2017 | 3.214M |
| September 30, 2017 | 13.17M |
| June 30, 2017 | 10.04M |
| December 31, 2016 | 16.53M |
| September 30, 2016 | 20.00M |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 27.45M |
| Perspective Therapeutics, Inc. | 82.13M |
| MiMedx Group, Inc. | 15.38M |
| Abbott Laboratories | 3.128B |
| AngioDynamics, Inc. | 29.45M |